Literature DB >> 10823818

Characterization of the recombinant IKK1/IKK2 heterodimer. Mechanisms regulating kinase activity.

Q K Huynh1, H Boddupalli, S A Rouw, C M Koboldt, T Hall, C Sommers, S D Hauser, J L Pierce, R G Combs, B A Reitz, J A Diaz-Collier, R A Weinberg, B L Hood, B F Kilpatrick, C S Tripp.   

Abstract

Nuclear factor kappa B (NF-kappaB) is a ubiquitous, inducible transcription factor that regulates the initiation and progression of immune and inflammatory stress responses. NF-kappaB activation depends on phosphorylation and degradation of its inhibitor protein, IkappaB, initiated by an IkappaB kinase (IKK) complex. This IKK complex includes a catalytic heterodimer composed of IkappaB kinase 1 (IKK1) and IkappaB kinase 2 (IKK2) as well as a regulatory adaptor subunit, NF-kappaB essential modulator. To better understand the role of IKKs in NF-kappaB activation, we have cloned, expressed, purified, and characterized the physiological isoform, the rhIKK1/rhIKK2 heterodimer. We compared its kinetic properties with those of the homodimers rhIKK1 and rhIKK2 and a constitutively active rhIKK2 (S177E, S181E) mutant. We demonstrate activation of these recombinantly expressed IKKs by phosphorylation during expression in a baculoviral system. The K(m) values for ATP and IkappaBalpha peptide for the rhIKK1/rhIKK2 heterodimer are 0.63 and 0.60 micrometer, respectively, which are comparable to those of the IKK2 homodimer. However, the purified rhIKK1/rhIKK2 heterodimer exhibits the highest catalytic efficiency (k(cat)/K(m)) of 47.50 h(-1) micrometer(-1) using an IkappaBalpha peptide substrate compared with any of the other IKK isoforms, including rhIKK2 (17.44 h(-1) micrometer(-1)), its mutant rhIKK2 (S177E, S181E, 1.18 h(-1) micrometer(-1)), or rhIKK1 (0.02 h(-1) micrometer(-1)). Kinetic analysis also indicates that, although both products of the kinase reaction, ADP and a phosphorylated IkappaBalpha peptide, exhibited competitive inhibitory kinetics, only ADP with the low K(i) of 0.77 micrometer may play a physiological role in regulation of the enzyme activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10823818     DOI: 10.1074/jbc.M000296200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

Review 1.  Oncogenic activation of NF-kappaB.

Authors:  Louis M Staudt
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

2.  Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects.

Authors:  Daisuke Ibi; Mario de la Fuente Revenga; Nebojsa Kezunovic; Carolina Muguruza; Justin M Saunders; Supriya A Gaitonde; José L Moreno; Maryum K Ijaz; Vishaka Santosh; Alexey Kozlenkov; Terrell Holloway; Jeremy Seto; Aintzane García-Bea; Mitsumasa Kurita; Grace E Mosley; Yan Jiang; Daniel J Christoffel; Luis F Callado; Scott J Russo; Stella Dracheva; Juan F López-Giménez; Yongchao Ge; Carlos R Escalante; J Javier Meana; Schahram Akbarian; George W Huntley; Javier González-Maeso
Journal:  Nat Neurosci       Date:  2017-08-07       Impact factor: 24.884

3.  Crystal structure of a human IκB kinase β asymmetric dimer.

Authors:  Shenping Liu; Yohann R Misquitta; Andrea Olland; Mark A Johnson; Kerry S Kelleher; Ron Kriz; Laura L Lin; Mark Stahl; Lidia Mosyak
Journal:  J Biol Chem       Date:  2013-06-21       Impact factor: 5.157

Review 4.  Inhibitory kappa B Kinases as targets for pharmacological regulation.

Authors:  Carly Gamble; Kathryn McIntosh; Rebecca Scott; Ka Ho Ho; Robin Plevin; Andrew Paul
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

5.  Increased O-Linked N-Acetylglucosamine Modification of NF-ΚB and Augmented Cytokine Production in the Placentas from Hyperglycemic Rats.

Authors:  Vanessa Dela Justina; Jéssica S Gonçalves; Raiany Alves de Freitas; Adriany Dias Fonseca; Gustavo T Volpato; Rita C Tostes; Fernando S Carneiro; Victor Vitorino Lima; Fernanda R Giachini
Journal:  Inflammation       Date:  2017-10       Impact factor: 4.092

6.  Activation of the NF-kappaB pathway in human cytomegalovirus-infected cells is necessary for efficient transactivation of the major immediate-early promoter.

Authors:  Ian B DeMeritt; Liesl E Milford; Andrew D Yurochko
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  The IkappaB kinases IKKalpha and IKKbeta are necessary and sufficient for skeletal muscle atrophy.

Authors:  Darin Van Gammeren; Jeffrey S Damrauer; Robert W Jackman; Susan C Kandarian
Journal:  FASEB J       Date:  2008-09-30       Impact factor: 5.191

8.  Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer.

Authors:  Jian-Ping Guo; Shao-Kun Shu; Lili He; Yi-Chun Lee; Patricia A Kruk; Seija Grenman; Santo V Nicosia; Gil Mor; Michael J Schell; Domenico Coppola; Jin Q Cheng
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

9.  Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen.

Authors:  Lloyd T Lam; R Eric Davis; Vu N Ngo; Georg Lenz; George Wright; Weihong Xu; Hong Zhao; Xin Yu; Lenny Dang; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-22       Impact factor: 11.205

10.  Loss of p53 enhances catalytic activity of IKKbeta through O-linked beta-N-acetyl glucosamine modification.

Authors:  Keiko Kawauchi; Keigo Araki; Kei Tobiume; Nobuyuki Tanaka
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.